Effect of Anti-FasL and/or Anti-TNFα Antibodies on GVHD-Associated Lymphoid Hypoplasia
Mice . | Cell No. (×107) . | |||||
---|---|---|---|---|---|---|
H-2Kd+Kb+ . | H-2Kd−Kb+ . | |||||
CD4+ . | CD8+ . | B220+ . | CD4+ . | CD8+ . | B220+ . | |
Normal | 2.1 ± 0.11 | 1.5 ± 0.57 | 2.8 ± 0.80 | — | — | — |
GVHD | 0.2 ± 0.02 | 0.2 ± 0.02 | 0.7 ± 0.06 | 0.4 ± 0.06 | 0.3 ± 0.07 | 1.3 ± 0.60 |
Anti-FasL | 1.2 ± 0.05 | 1.7 ± 0.06 | 1.8 ± 0.33 | 2.2 ± 0.70 | 2.5 ± 0.84 | 1.6 ± 0.52 |
Anti-TNFα | 1.2 ± 0.46 | 1.1 ± 0.29 | 1.4 ± 0.02 | 2.4 ± 0.30 | 2.0 ± 0.30 | 1.9 ± 0.10 |
Anti-FasL + anti-TNFα | 1.6 ± 0.20 | 1.9 ± 0.45 | 2.0 ± 0.65 | 3.3 ± 0.27 | 3.3 ± 0.39 | 2.8 ± 0.90 |
Mice . | Cell No. (×107) . | |||||
---|---|---|---|---|---|---|
H-2Kd+Kb+ . | H-2Kd−Kb+ . | |||||
CD4+ . | CD8+ . | B220+ . | CD4+ . | CD8+ . | B220+ . | |
Normal | 2.1 ± 0.11 | 1.5 ± 0.57 | 2.8 ± 0.80 | — | — | — |
GVHD | 0.2 ± 0.02 | 0.2 ± 0.02 | 0.7 ± 0.06 | 0.4 ± 0.06 | 0.3 ± 0.07 | 1.3 ± 0.60 |
Anti-FasL | 1.2 ± 0.05 | 1.7 ± 0.06 | 1.8 ± 0.33 | 2.2 ± 0.70 | 2.5 ± 0.84 | 1.6 ± 0.52 |
Anti-TNFα | 1.2 ± 0.46 | 1.1 ± 0.29 | 1.4 ± 0.02 | 2.4 ± 0.30 | 2.0 ± 0.30 | 1.9 ± 0.10 |
Anti-FasL + anti-TNFα | 1.6 ± 0.20 | 1.9 ± 0.45 | 2.0 ± 0.65 | 3.3 ± 0.27 | 3.3 ± 0.39 | 2.8 ± 0.90 |
Cell numbers of CD4+ T, CD8+ T, and B220+ B cells of host (H-2Kd+Kb+) or donor (H-2Kd−Kb+) origin in the splenocytes from normal CBF1, GVHD, or anti-FasL antibody-treated and/or anti-TNFα antibody-treated mice on day 21 were calculated from the total numbers of splenocytes recovered, and the percentages of each subpopulation were determined using three-color flow cytometric analysis. Data represent the mean ± SD of 5 mice in each group.